Table 2.

Estimated Prevalence of Lipoatrophy by Intent-to-Treat Analysis

Variable	EFV + TDF-FTC (n = 56)	EFV + ABC-3TC (n = 53)	ATV-r + TDF-FTC (n = 45)	ATV-r + ABC-3TC (n = 49)	Total (n = 203)
No. of subjects with ≥ 10% limb fat loss	8	10	7	8	33
Prevalence of ≥ 10% limb fat loss (primary analysis), % (95% CI)	14.3 (6.4–26.2)	18.9 (9.4–32.0)	15.6 (6.5–29.5)	16.3 (7.3–29.7)	16.3 (11.5–22.1)
No. of subjects with ≥ 20% limb fat loss	5	2	0	3	10
Prevalence of ≥ 20% limb fat loss (post hoc analysis), % (95% CI)	8.9 (3.0–19.6)	3.8 (0.5–13.0)	0.0 (0.0–7.9)	6.1 (1.3–16.9)	4.9 (2.4–8.9)

NOTE. Loss of lipoatrophy defined as ≥ 10% limb fat and ≥ 20% limb fat from baseline to week 96. ABC, abacavir; ATV/r, atazanavir-ritonavir; CI, confidence interval; EFV, efavirenz; FTC, emtricitabine; TDF, tenofovir DF; 3TC, lamivudine.